MedTrace Logo

The Effect of Fenoldopam in Solitary Partial Nephrectomy Surgery

NCT00743106 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2018-09-19

Study results available
· View outcomes & findings →

Summary

This trial will study the effects of fenoldopam on renal function in patients who have a single kidney undergoing surgery to remove part of that kidney secondary to renal cell carcinoma. The investigators will monitor and evaluate throughout the perioperative course the kidney function. Normally kidney function is predicted to show a worsening followed by an improvement after surgery.

The investigators want to specifically identify if the use of fenoldopam lessens the injury to the kidney with this surgery.

Conditions

  • Partial Nephrectomy

Interventions

DRUG

Fenoldopam

Fenoldopam (0.1 \~g/kg/min)started during surgery and lasting for a total of 24 hours

DRUG

Placebo

Placebo infusion(0.9% Nacl) beginning during surgery and lasting for up 24 hours post surgery

Sponsors & Collaborators

  • The Cleveland Clinic

    lead OTHER

Principal Investigators

  • Jerome O'Hara, MD · The Cleveland Clinic

  • Daniel I Sessler, MD · Cleveland Clnic

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-09-30
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00743106 on ClinicalTrials.gov